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THE PURPOSE AND SCOPE  
OF THE GUIDELINES
Epilepsy is the most common neurological disorder dur-
ing pregnancy [1]. About one-third of women with epilepsy 
are of childbearing age. Statistically, between 0.3% and 0.5% 
of births occur in women with epilepsy [2]. Every year in Poland 
epilepsy poses a threat to the health of some 1800 pregnant 
women and their fetuses. According to British studies, the 
risk of death in pregnant women with epilepsy increases ten-
fold compared to pregnant women without epilepsy, mainly 
due to sudden unexpected death in epilepsy (SUDEP) [3]. 
Diagnostic and therapeutic advances in the field of epilepsy 
have contributed to better seizure control. As a result, more 
and more women with epilepsy become pregnant and more 
than 90% give birth to healthy children [4, 5]. In order to 
avoid irregularities in the management of women suffering 
from epilepsy, it is very important to create standards for the 
management of women treated for epilepsy, both for those 
who are already pregnant and those who plan pregnancy. 
Thus the first edition of guidelines regarding management 
and care in women with epilepsy during preconception 
period and also during pregnancy, delivery, and postpartum 
were prepared by the experts of Polish Society of Epilep-
tology and Polish Gynecological Society. The diagnosis, 
seizures classification and therapy of epilepsy were not 
included into the guidelines. 
The neurologists, gynecologists and family doctors 
should inform that the women with epilepsy could benefit 
from planning pregnancies to reduce the risk of fetal con-
genital malformations. Due to increased awareness and 
knowledge concerning epilepsy, the number of planned 
pregnancies is increasing, but 40% are still unplanned. The 
risk of major congenital malformations in the fetus increases 
in women with epilepsy taking antiepileptic drugs [6]. Fears 
of women with epilepsy in relation to the adverse effects of 
antiepileptic drugs on infants can lead to arbitrary withdraw-
al or dose reduction of antiepileptic drugs, and thus increase 
the risk of seizures and even SUDEP [4]. Therefore, women of 
reproductive age (15–44 years) treated for epilepsy should 
receive care from specialist epilepsy and gynecology clinics.
DIAGNOSIS OF EPILEPSY
Epilepsy is a heterogeneous group of diseases of the brain, 
the common symptoms of which are clinical seizures. After 
diagnosis of epilepsy, a neurologist determines the type of 
epileptic seizure and suggests appropriate treatment for 
epilepsy. Based on the course of the disease, neurologist 
can assess the degree of risk of neurological complications 
in pregnancy. Women who have not experienced seizures 
for at least 10 years (including five years without antiepilep-
tic drugs) and those who were diagnosed with childhood 
epileptic syndrome, but have not experienced seizures in 
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their adult life are considered as no longer suffering from 
epilepsy [7]. Women with a history of epilepsy who have no 
risk of unprovoked epileptic seizures may be classified as 
a low-risk group. Uncontrolled tonic-clonic seizures are the 
strongest risk factors for SUDEP, which is the main cause of 
death in pregnancy [3]. Seizures occurring for the first time in 
the second half of pregnancy do not have to be of epileptic 
origin and eclampsia treatment should be implemented 
according to the agreed protocol until a final diagnosis is 
reached. Tonic-clonic seizures in eclampsia combined with 
loss of consciousness are often preceded by an increase in 
blood pressure, proteinuria, thrombocytopenia and an in-
crease in serum transaminase. However, in nearly 40% of cas-
es, these irregularities may only appear within 24 hours [8]. 
A differential diagnosis should also take account of other 
causes, such as cardiac, metabolic, or psychogenic reasons [8]. 
Psychogenic non-epileptic seizures can coexist with epilep-
tic seizures and are a complex diagnostic and therapeutic 
problem requiring multidisciplinary psychological and psy-
chiatric management.
PRECONCEPTION CARE  
IN WOMEN WITH EPILEPSY
The purpose of preconception care in women with epi-
lepsy is to reduce the risk of fetal abnormalities and disorders 
of the subsequent development of the child through the 
optimization of pharmacological treatment and folate sup-
plementation, as well as to control seizures in pregnancy. It 
is important to explain the problem to the patient and her 
relatives and emphasize that the potential teratogenic fac-
tor, i.e. an antiepileptic drug, starts working in the first days 
after conception. At least until the end of the first trimester 
of pregnancy, the lowest effective dose of the most ap-
propriate AED should be used in order to reduce the risk of 
major birth defects [6]. Withdrawal of medication for at least 
a year before the planned pregnancy can be considered in 
women after a three-year seizure-free period [9]. Pregnant 
women who have experienced seizures a year before con-
ception require increased monitoring and treatment for 
epilepsy. Most women (67%) do not experience seizures 
during pregnancy. Between 74% and 92% of women who 
have been seizure-free for at least 9 months to 1 year before 
pregnancy will remain free of seizures during pregnancy [4]. 
Data from EURAP (European Registry of Antiepileptic Drugs 
and Pregnancy) have shown that pregnant women with 
idiopathic generalized epilepsy are more likely to be free 
of seizures (74%) than those with focal epilepsy (60%) [10]. 
Women with epilepsy should be informed that a few 
safety precautions can greatly reduce the risk of seizures 
and minimize concern about the impact of AEDs on their 
infants. Studies have shown that 87% of women would 
like to consult their doctors on the impact of seizures and 
antiepileptic drugs on their unborn children, and about 
half of them would like to be more active in the discussion 
about their treatment [11]. Moreover, if risk factors for the 
inheritance of epilepsy are known or if a patient feels very 
strong anxiety and fear that her child will inherit the disease, 
she should be offered genetic counseling.
Antiepileptic drugs and their teratogenic effects
Women with epilepsy who plan to become pregnant 
should be under the care of physicians with expertise in 
the treatment of epilepsy. The women should consciously 
participate in the choice of drugs and doses on the basis 
of reliable information about the related risk to the fetus 
and the control of seizures in the mother. Women with 
epilepsy should be informed about the fact that the major-
ity of women give birth to healthy children, and the risk of 
congenital defects is low if the child is not exposed to AEDs 
during the periconceptional period. In women with epilepsy 
not using AEDs, the risk of congenital defects in children is 
similar to that in the population [6]. 
The risk of major birth defects of the fetus is depen-
dent on the type, nuber and dose of AEDs Among AEDs, 
lamotrigine (LTG), levetiracetam (LEV), carbamazepine (CBZ) 
and oxcarbazeine (OXC) used in monotherapy in small doses 
cause the least risk of major malformations in the offspring 
[6, 10, 12–14]. The most common major birth defects as-
sociated with AEDs involve the neural tube, heart, urinary 
tract, skeletal system and cleft palate. Sodium valproate 
causes an increased risk of neural tube defects, facial cleft, 
hypospadias; phenobarbital (PB) and phenytoin (DPH) may 
cause heart defects; DPH, CBZ, topiramat (TPM) may lead to 
cleft palate in the fetus. It is worth noting that PB and DPH 
are used extremely rarely in the Polish population. A sys-
tematic review and meta-analysis of 59 studies estimating 
the incidence of congenital malformations in the fetuses of 
mothers using different AEDs indicate that the highest risk 
of congenital malformations in fetuses occurs in women 
taking sodium valproate (10.7 of 100, 95% CI: 8.16–13.29) 
or combination therapy (16.8 of 100, 95% CI: 0.51–33.05) 
compared to the fetuses of mothers not suffering from epi-
lepsy (2.3 of 100, 95% CI: 1.46–3.1) [13]. The EURAP’s data 
show that the lowest rates of malformations were observed 
in women who received LTG in a dose less than 300 mg 
per day (2 of 100, 95% CI: 1.19–3.24) and CBZ in a dose less 
than 400 mg per day (3.4 of 100, 95% CI: 1.11–7.71) [10]. 
The rates of major congenital anomalies in the records of 
Great Britain and Ireland were also lower in women taking 
levetiracetam (LEV) in monotherapy (0.7 of 100, 95% CI: 
0.19–2.51) than in the group that took combination therapy 
(5.6 of 100, 95% CI: 3.54–8.56) [14]. There are insufficient data, 
including the small amount of pregnant women, to assess 
the risk of birth defects for other AEDs used in monotherapy, 
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such as gabapentin (GBP), lacosamide (LCM), oxcarbazepine 
(OXC), pregabalin (PGB), topiramate (TPM) and zonisamide 
(ZNS) [6]. However, although available data on the use of 
new-generation AEDs are still limited, they indicate that 
these drugs have a favorable safety profile and cause a lower 
risk of teratogenic effects than the older drugs. The risk of 
major birth defects in a subsequent pregnancy is increased 
(16.8 of 100) if it occurred in a child in a previous pregnancy. 
There were no significant relationships between the 
type of epilepsy, tonic-clonic seizure in the first trimester 
of pregnancy and birth defects. Women with epilepsy and 
their partners should be informed about the possible ad-
verse effects of sodium valproate on the long-term neu-
ral development of the fetus in the womb [6]. Studies of 
preschool children whose mothers took valproate during 
pregnancy show that as many as 30–40% of these children 
experience delays in the early stages of development such 
as delays in talking and walking, poorer intellectual abilities, 
poor language skills (speaking and understanding), memory 
impairment and autism spectrum disorders. Compared to 
mothers without epilepsy and mothers with epilepsy not 
receiving AEDs, the intelligence quotient (IQ) measured 
in school-age children (6 years) exposed to valproate in 
utero was an average of 7–10 points lower than in children 
exposed to other antiepileptic drugs (data indicate that 
the risk of deterioration of intellectual abilities may be in-
dependent of the mother’s IQ) [15, 16]. Based on limited 
evidence, CBZ and LTG do not seem to have this effect. In 
2014, the Cochrane Review demonstrated that there are no 
significant differences in the development and IQ of children 
exposed to antiepileptic drugs, such as CBZ, LTG and DPH, 
compared with the infants of mothers without epilepsy and 
the offspring of women with epilepsy not taking AEDs [17]. 
Very few studies have so far evaluated the cognitive abilities 
of the children of mothers using LEV during pregnancy, but 
preliminary results involving a limited number of respond-
ents suggest a slight risk of teratogenicity. Parents should 
be informed that data concerning the long-term sequelae 
of AEDs are based on observations of a small number of 
children. Little is known about other new AEDs and the use 
of combination therapy, but the lack of data should not be 
interpreted. Literature data and messages for healthcare 
professionals should be monitored on a regular basis, as 
they may contain new information on this subject. 
Folate supplementation
Antiepileptic drugs are a risk factor for reduced blood 
folate levels. Folate metabolism disorder is associated with 
a higher incidence of fetal abnormalities, such as neural tube 
defects, miscarriage, preeclampsia and intrauterine fetal 
growth inhibition [18]. When used in the periconceptional 
period, folates may have a beneficial effect on reducing 
the risk of deficits associated with exposure to AEDs [19]. 
Folate supplementation should begin at least three months 
before pregnancy and be continued during pregnancy, the 
postpartum period and breast-feeding. 
The recommended dose in women taking antiepileptic 
drugs is 400 μg plus another 400 μg, preferably in the form 
of active folate [20]. High doses of folate, 5 mg daily, are 
recommended only if the woman or her partner and their 
offspring suffer from neural tube defects. The use of doses 
above 5 mg is not justified and could lead to a lowered 
seizure threshold.
ANTENATAL CARE
Pregnant women with epilepsy should have access to 
regular, planned antenatal care provided by an interdisci-
plinary team, preferably in specialist centers ensuring the 
highest level of perinatal and neurological care. Women 
taking antiepileptic drugs who have become unintentionally 
pregnant should have an urgent opportunity to discuss the 
procedure with a specialist to avoid a sudden reduction or 
withdrawal of AEDs without proper consultation. From the 
moment of conception, pregnant women should consult 
a gynecologist-obstetrician at least every four weeks and 
a neurologist at least once a trimester.
Maternity care during pregnancy
Physicians providing care for pregnant women with 
epilepsy should be aware of a small but significant increase 
in the risk of complications during pregnancy, especially 
in women taking AEDs [4, 5, 21]. A review of 38 studies of 
women with epilepsy conducted in 2015 showed that there 
was a slightly higher risk of: spontaneous abortion (OR 1.54, 
95% CI: 1.02–2.32); antepartum hemorrhage (OR 1.49, 
95% CI: 1.01–2.20); hypertensive disorders (OR 1.37, 95% CI: 
1.21–1.55); induction of labor (OR 1.67, 95% CI: 1.31–2.11); 
cesarean section (OR 1.40, 95% CI: 1.23–1.58); premature 
birth (less than 37 weeks; OR 1.16, 95% CI: 1.01–1.34); fetal 
growth inhibition (OR 1.26, 95% CI: 1.20–1.33); and post-
partum hemorrhage (OR 1.29, 95% CI: 1.13–1.49) in women 
with epilepsy compared to women without epilepsy [5]. No 
differences were found between the two groups in terms of 
perinatal death. A comparison of women with epilepsy tak-
ing and not taking AEDs showed a higher risk of induction 
of labor (OR 1.40, 95% CI: 1.05–1.85), fetal growth inhibition 
(OR 3.51, 95% CI: 1.23–10.01) and postpartum hemorrhage 
(OR 1.33, 95% CI: 1.16–1.54) in the group receiving AEDs. 
There were no significant differences between the two groups 
in terms of hypertensive disorders, cesarean section, sponta-
neous abortion, antenatal hemorrhage, preterm birth and fe-
tal death. Studies comparing women receiving monotherapy 
and polypharmacy showed a greater risk of cesarean section 
in the group receiving combination therapy (OR 1.47, 
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It is recommended that these patients are not left unat-
tended at night.
Serum concentrations of most of new generation an-
tiepileptic drugs may fluctuate during pregnancy due to 
changes in pharmacokinetics at the stages of absorption, 
metabolism, excretion and hemodilution. It has been found 
that concentrations of lamotrigine, levetiracetam and oxcar-
bamazepine in pregnant women may fall by as much as 30% 
to 50% [6]. Reduced concentrations of drugs can exacerbate 
seizures. Some doctors prophylactically increase the dose of 
drug during pregnancy, while others have concerns about 
the potential side effects of increased intake of drugs during 
pregnancy without clear preponderance of benefit over risk. 
It is therefore recommended to monitor the concentration 
of these drugs in blood serum before pregnancy and at least 
once in each trimester of pregnancy. It is recommended that 
women with epilepsy are informed that some types of epi-
lepsy and some AEDs carry an increased risk of depression, 
depressed mood, poor concentration, fatigue, irritability or 
anger [11]. It is emphasized that women should be encour-
aged to perform self-observation. 
DELIVERY IN WOMEN WITH EPILEPSY
Perinatal care of pregnant women with epilepsy should 
take place in specialist centers providing the highest level 
of perinatal and neurological care. Women with epilepsy 
should be reassured that the majority will have uncompli-
cated deliveries and receive appropriate care in the event 
of complications.
The diagnosis of epilepsy per se is not an indication for 
planned cesarean section or induction of labor. There is no 
indication for earlier delivery in women with epilepsy without 
obstetric risk factors whose seizures are well controlled. Ce-
sarean section may be considered for a small percentage of 
women with a significant increase in seizures, cluster seizures 
and a high risk of status epilepticus. Obstetrical procedures in 
women with epilepsy do not deviate from accepted princi-
ples of modern obstetrics. However, continuous cardiotoco- 
graphic monitoring is recommended during labor.
Pregnant women with epilepsy should be informed that 
the risk of seizures during labor is low and ranges from about 
1% to 2% and from 1% to 2% within 24 hours after birth. 
Antiepileptic drugs should be continued during labor ac-
cording to neurologist’s recommendations. If they cannot be 
administered orally, they should be administered parenterally 
(valproic acid, levetiracetam and phenytoin are administered 
intravenously). Seizures during labor can lead to hypoxia in 
the mother (due to apnea during seizure), as well as fetal 
hypoxia and acidosis secondary to increased tension of the 
uterus. Adequate hydration and pain relief by epidural anes-
thesia reduces the risk of seizures during labor. Nitrous oxide 
can also be used as an analgesic. Administration of pethidine 
95% CI: 1.07–2.02). There were no differences in spontane-
ous miscarriage, premature birth (before 36 or 37 weeks) 
and antepartum hemorrhage in both groups. There were 
also no differences in gestational age and stillbirths.
Due to an increased risk of fetal abnormalities, pregnant 
women with epilepsy should have ultrasound scans (which 
are generally recommended in pregnancy) performed by 
qualified professionals. Ultrasound performed in the first 
and second trimesters of pregnancy can detect abnormali-
ties in the anatomy of the fetus. If fetal defects are detected, 
perinatologists and neonatologists must consult in order to 
identify therapeutic opportunities during and after preg-
nancy. Parents should be able to choose the procedure.
The children of women with epilepsy taking AEDs have 
an increased risk of lower weight in relation to gestational 
age. A physician performing an ultrasound examination in 
the third trimester of pregnancy should pay special atten-
tion to fetal biometry. Fetal health should be monitored in 
pregnancies with fetal growth restriction. It is recommended 
to perform fetal biometry and ambulatory cardiotocogra-
phy after 36 weeks in pregnancies not complicated by fetal 
growth restriction.
Antiepileptic drugs, such as phenytoin, carbamazepine 
and phenobarbital may increase the metabolism of corti-
costeroids, which in turn can lead to reduced therapeutic 
efficacy for the prevention of respiratory distress syndrome 
in infants in women with epilepsy taking enzyme-induc-
ing AEDs, who are at risk of premature birth. However the 
benefits of increase dose of corticosteroids have not been 
proved and, the routine doubling of corticosteroid dose is 
not recommended [22]. 
Neurological care during pregnancy
Risk factors for seizures, such as lack of sleep, stress, 
irregular intake of AEDs, as well as the type and frequency 
of seizures should be evaluated in pregnant women with 
epilepsy. If women who are at a high risk of seizures have to 
be admitted to hospital before labor has begun, they should 
be placed in a location that allows the medical personnel 
or relatives to continuously monitor the patients. During 
subsequent visits to the clinic, mothers should always be 
examined for their ability to cope with daily duties, memory, 
concentration, sleep quality, dose regimen, as well as the 
frequency and type of seizures. Symptoms such as an in-
crease in the number of seizures, fatigue, dizziness, as well 
as the occurrence of potential risk factors for seizures such 
as lack of sleep and stress may require consultation with 
a neurologist, who may change the dose of medication, 
add new drugs or recommend hospitalization. Women with 
frequent seizures are advised to stay with a companion for 
as long as possible. Patients with seizures that occur during 
sleep or without witnesses are at a high risk of SUDEP [3]. 
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is contraindicated because of the risk of a lowered seizure 
threshold. Early use of epidural anesthesia can minimize risk 
factors for seizures during labor, such as: hyperventilation, 
sleep deprivation, pain and stress. If general anesthesia is 
required, anesthetics such as pethidine and ketamine must 
be avoided (they decrease the seizure threshold).
There are no known contraindications to the use of any 
labor-inducers in women with epilepsy taking AEDs. There 
is no evidence that antiepileptic drugs affect labor-induc-
ing medications. It must be noted that risk factors, such 
as stress, insomnia and dehydration increase in women 
with prolonged induction and efforts should be taken to 
minimize them. 
THE POSTPARTUM PERIOD  
IN WOMEN WITH EPILEPSY
Due to increased stress, lack of sleep, anxiety and miss-
ing a dose, the immediate period after birth involves a high 
risk of more frequent seizures. Mothers should be supported 
in the postpartum period to minimize risk factors for sei-
zures; in particular, they should be provided with a con-
tinuous 4–6 hour period of sleep [19]. Taking AEDs is not 
a contraindication to breastfeeding, because the benefits 
outweigh the risks. Many women receive higher doses of 
antiepileptic drugs in late pregnancy compared with the 
doses used before pregnancy. In the postpartum period, 
the physiological changes that take place during pregnancy, 
such as increased renal and liver clearance and hemodilu-
tion, are reversed and there is a risk that high doses of AEDs 
will be toxic for the newborn. If the dose is increased during 
pregnancy, the concentration of the drug should be meas-
ured within 10 days after delivery and the dose should be 
adequately reduced in order to avoid toxicity after delivery 
[6, 19]. If signs of toxicity of AEDs are observed in the post-
partum period (e.g. drowsiness, double vision or balance 
disorder), urgent neurological evaluation is required.
Neonates born to women taking AEDs should be moni-
tored for adverse effects (drowsiness, difficulty in breastfeed-
ing, excessive sedation or withdrawal symptoms — excessive 
irritability and crying) associated with exposure to AEDs in 
utero. Care for women with epilepsy and their children should 
be provided by perinatological centers having the ability to 
determine concentrations of AEDs and cooperating with neu-
rological centers specializing in care for patients with epilepsy.
Women with epilepsy who take antiepileptic drugs dur-
ing pregnancy should be encouraged to breastfeed. Mothers 
should be informed that according to current knowledge, the 
risk of cognitive complications is not increased in children 
exposed to antiepileptic drugs contained in the milk of moth-
ers taking AEDs [6, 19]. It must be remembered that all an-
tiepileptic drugs penetrate into the mammary gland and are 
secreted in breast milk. However, their concentration is much 
lower in the milk than in the serum of a breastfeeding patient. 
A lack of breastfeeding may cause abstinence syndrome in 
the newborn, which is more dangerous than breastfeeding. 
The symptoms of drowsiness in the newborn may occur in 
cases where the mother is administered high doses of phe-
nobarbital, primidone and benzodiazepines. In such cases, 
cessation of breastfeeding should be taken into account. 
A prospective study has shown that the psychomotor devel-
opment of children who were exposed to antiepileptic drugs 
in utero and breastfed in the postpartum period was better 
after 6 and 18 months compared with children who were not 
breastfed or were breastfed for less than 6 months [6, 19]. 
Women who had no seizures during pregnancy can breast-
feed their babies. However, those who experienced seizures 
should breastfeed only in the presence of a family member 
or medical personnel, if possible. 
Women with epilepsy are at an increased risk of depres-
sion in the postpartum period compared with mothers with-
out epilepsy. Symptoms of postpartum depression include 
depressed mood, fatigue, lack of appetite, and feelings of 
tension or anxiety. Early intervention can improve the qual-
ity of women’s lives. 
CONTRACEPTION IN WOMEN WITH EPILEPSY
Contraception is a key problem for women with epilepsy 
of childbearing age. Planning and conscious preparation for 
pregnancy allows women to choose the least burdensome 
drug (with the lowest risk of teratogenicity), start increased 
supplementation of folic acid, as well as to optimize seizure 
control in the periconceptional period [23]. Contraceptive 
methods in patients with epilepsy should be selected ac-
cording to criteria used for the entire population, taking into 
account additional criteria: the impact of contraceptives on 
the severity of the disease; the impact of contraceptives on 
the effectiveness of antiepileptic drugs; the impact of antie-
pileptic drugs on the effectiveness of contraceptives. Previ-
ous studies have shown no impact of non-hormonal con-
traceptives on any of the above criteria [24]. 
Hormonal contraception
Regardless of the form and route of administration, 
combined contraception increases the incidence of sei-
zures through the three main mechanisms [24, 25]: 1) di-
rect, non-genomic effect on neuronal receptors (GABA and 
other receptors); 2) direct genomic effect on intracellular 
targets such as steroid receptors; 3) indirect effect on the 
metabolism of antiepileptic drugs through the induction 
of cytochrome P450 enzymes. Antiepileptic drugs can in-
duce the cytochrome P450 family of hepatic enzymes and 
isoenzyme 3A4 in particular by increasing the metabolism 
of ethinyl estradiol (EE), and consequently decrease the 
effectiveness of birth control [26].
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The American Academy of Neurology recommends the 
use of oral contraceptives containing 50 micrograms of EE. 
While this is an expert opinion, there are no studies proving 
that pills containing 50 micrograms of EE in combination 
with the anti-inducers of liver enzymes are more effective. 
There are currently no preparations of similar composition 
on the Polish market because of their proven harm! Trans-
dermal patches and vaginal rings have the same sensitivity 
to selected antiepileptic drugs.
Gestagen-only contraceptives are less sensitive to liver 
enzyme inducers and are the recommended method of hor-
monal contraception in women with epilepsy [27]. Continuous 
methods are particularly recommended, such as the levonor- 
gestrel intrauterine device and subcutaneous etonogestrel im-
plant. However, in the case of intramuscular administration of 
medroxyprogesterone acetate, shortening the time between 
injections, to 8–10 weeks instead of the standard 12 weeks, is 
suggested. Not all antiepileptic preparations have enzyme-in-
ducing effects. Table 1 lists the drugs that reduce the effective-
ness of contraception and those that have no effect on it [28]. 
Special attention should be paid to lamotrigine. The use of oral 
contraceptives reduces its concentration by nearly 50% [29]. In 
contrast to other antiepileptic drugs, lamotrigine is eliminated 
by binding to glucuronic acid [30]. Patients receiving hormonal 
contraception in combination with lamotrigine should have 
its serum concentration monitored due to a possible reduc-
tion in the effectiveness of antiepileptic treatment. Published 
studies have shown no effect of progestin-only contraceptives 
on lamotrigine concentration [23]. 
Table 1. Antiepileptic drugs and their impact on the effectiveness 
of hormonal contraception
Antiepileptic drugs that reduce the effectiveness  
of contraception
Carbamazepine 
Felbamate 
Lamotrigine — only reduces the level of progesterone
Oxcarbazepine 
Phenobarbital
Phenytoin 
Primidone 
Rufinamide 
Topiramate — reduces the level of ethinyl estradiol by about 30%
Antiepileptic drugs that do not affect the effectiveness  
of contraception
Acetazolamide 
Benzodiazepines: clobazam, clonazepam
Ethosuccimide 
Gabapentin 
Lacosamide
Levetiracetam 
Pregabalin 
Sodium valproate 
Tiagabine 
Vigabatrin 
Zonisamide
Table 2. Contraception in women with epilepsy 
Barrier methods of birth control and the intrauterine device with 
copper may be recommended according to the rules applicable in 
the whole population
Gestagen-only contraceptives, which are less sensitive to liver 
enzyme inducers, are the recommended method of hormonal 
contraception in women with epilepsy
The levonorgestrel intrauterine device and subcutaneous 
etonogestrel implant are the contraceptive methods whose 
effectiveness are not affected by antiepileptic drugs inducing 
P450 enzymes and should be recommended as first-choice 
contraceptives
In the case of intramuscular administration of medroxyprogesterone 
acetate, the time between injections must be shortened to 
8–10 weeks
Regardless of the form and route of administration, combined 
estrogen-progestogen contraceptives increase the incidence of 
seizures and should not be used in women with epilepsy
Managing Epilepsy in Women of Childbearing Age — key points
Epilepsy is not a contraindication to having children: more than 90% 
of women with epilepsy give birth to healthy children
The planning and preparation for pregnancy are essential and 
necessary in women with epilepsy
The fetal malformations’ risk stratification should reflect the type 
and dose of AEDs, and the use of mono or polytherapy regiments
Epilepsy is not a contraindication to natural vaginal birth, epidural 
childbirth and breastfeeding
Effective contraception is possible in women with epilepsy who do 
not plan pregnancy
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